Geneva, Switzerland, May 12, 2025-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26FDA’s decision follows ...
The sigma-1 receptor is an important new therapeutic drug target for Alzheimer’s disease (AD). Here, we reported that SOMCL-668, a novel selective and potent sigma-1 receptor allosteric modulator, is ...
Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, June 25, 2026-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage ...
ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in ...
Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...
A Vanderbilt University patent discloses new muscarinic M4 receptor positive allosteric modulators and agonists reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, ...
Novel nicotinamide phosphoribosyltransferase (NAMPT) positive allosteric modulators (N-PAMs) have been discovered and evaluated by University of Illinois and University of Arizona investigators.
Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...
G-protein-coupled receptors (GPCRs) are a large and diverse family of cell surface receptors that play critical roles in transmitting extracellular signals to the interior of the cell. GPCRs represent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results